Clinical trials: Oral Phase
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
- Trial name
- NCT01959594
- Testing
- 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Male Subjects
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
This study is objective to evaluate the in vivo absorption, excretion and biotransformation pathways of [14C]-TPN171H in Chinese male healthy volunteers, and to reveal the overall pharmacokinetic characteristics of TPN171H in…
- Trial name
- NCT04655872
- Testing
- [14C]TPN171H
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Head and Neck Cancer
Vaccine Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00404339
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Robert Ferris
Type 2 Diabetes Mellitus
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00962065
- Testing
- LX4211 Low Dose, LX4211 High Dose
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
EPP, XLP
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
To evaluate the long-term safety and tolerability of oral dersimelagon.
- Trial name
- NCT05005975
- Testing
- MT-7117
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 286 people
- Sponsor
- Tanabe Pharma America, Inc.
PK in Healthy Volunteers
Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions
The present study is designed to assess the impact of concomitant food intake on the relative bioavailability of a single oral fexinidazole tablet administration.
- Trial name
- NCT01340157
- Testing
- Fexinidazole
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
This is a Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses
- Trial name
- NCT06179537
- Testing
- BLU-5937
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bellus Health Inc. - a GSK company
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers
This is a Phase 1 relative bioavailability study carried out in approximately 24 healthy male subjects and healthy female subjects of non childbearing potential to investigate the effects of formulation and food on the safety…
- Trial name
- NCT04581772
- Testing
- DNL343
- Where
- New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Healthy Volunteers
Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating single oral doses of AEF0117 in healthy adult male and female subjects.
- Trial name
- NCT03325595
- Testing
- AEF0117
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Diabetes
Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients
The study will be a non-randomized, open label, single dose, single blind, placebo control, single center, single arm study in Type I diabetes patients.
- Trial name
- NCT01120912
- Testing
- Oshadi Oral Insulin
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Oshadi Drug Administration
Menstrual Cycle, Oral Contraceptives
The Effect of Menstrual Cycle and Oral Contraceptive Pill Phase on Aspects of Exercise Physiology
This study will investigate the effect of menstrual cycle (MC) and oral contraceptive pill phase on aspects of exercise physiology and athletic performance in female athletes.
- Trial name
- NCT05683119
- Testing
- Exercise and blood draw
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Smoking Cessation
A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
1. To evaluate the absorption and elimination of varenicline Formulation A transdermal delivery system [TDS (patch)] compared to varenicline immediate release tablet (CHANTIX®). 2.
- Trial name
- NCT00661765
- Testing
- varenicline tartrate, varenicline free base
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Fallopian Tube Cancer, Ovarian Cancer
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00096239
- Testing
- CP-547,632
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Sjogrens Syndrome
Nipocalimab in Moderate to Severe Sjogren's Disease
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
- Trial name
- DAFFODIL (NCT06741969)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 254 sites in United States, Argentina and 26 more
- Volunteers
- 655 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease.
- Trial name
- NCT03168256
- Testing
- CF101 2mg, CF101 3mg, Apremilast 30mg
- Where
- 30 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 528 people
- Sponsor
- Can-Fite BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.